| Renal Cell Carcinoma
Inlyta vs Sutent
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Inlyta vs Sutent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSutent has a higher rate of injection site reactions vs Inlyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sutent but not Inlyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inlyta
Sutent
At A Glance
Oral
Twice daily
VEGFR tyrosine kinase inhibitor
Oral
Daily
Multi-targeted RTK inhibitor
Indications
- Renal Cell Carcinoma
- Gastrointestinal Stromal Tumors
- Renal Cell Carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
Dosing
Renal Cell Carcinoma (first-line, with avelumab) 5 mg orally twice daily combined with avelumab 800 mg IV every 2 weeks; dose escalation may be considered at intervals of 2 weeks or longer.
Renal Cell Carcinoma (first-line, with pembrolizumab) 5 mg orally twice daily combined with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks IV; dose escalation may be considered at intervals of 6 weeks or longer.
Renal Cell Carcinoma (second-line, single agent) Starting dose 5 mg orally twice daily approximately 12 hours apart, with or without food; doses may be increased to 7 mg or 10 mg twice daily based on tolerability, or reduced to 3 mg or 2 mg twice daily for adverse reactions.
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma 50 mg orally once daily on Schedule 4/2 (4 weeks on, 2 weeks off); adjuvant RCC limited to a maximum of nine 6-week cycles.
Well Differentiated Pancreatic Endocrine Neoplasm 37.5 mg orally once daily until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Diarrhea, fatigue, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, musculoskeletal pain, constipation
Serious Hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, hepatotoxicity
Postmarketing Arterial aneurysms, dissections, and rupture (including aortic)
Most common (>=25%) Fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, thrombocytopenia.
Serious Hepatotoxicity, cardiovascular events, QT interval prolongation and Torsade de Pointes, hemorrhagic events, tumor lysis syndrome, thrombotic microangiopathy, proteinuria, dermatologic toxicities, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw, impaired wound healing.
Postmarketing Hemorrhage associated with thrombocytopenia, esophagitis, acalculous cholecystitis, hypersensitivity reactions including angioedema, serious infection, fistula formation, myopathy/rhabdomyolysis, renal impairment/failure, pulmonary embolism, pleural effusion, pyoderma gangrenosum, arterial aneurysms/dissections/rupture, arterial thromboembolic events.
Pharmacology
Axitinib is a selective inhibitor of receptor tyrosine kinases including VEGFR-1, VEGFR-2, and VEGFR-3, which are implicated in pathologic angiogenesis, tumor growth, and cancer progression; VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models.
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) including PDGFRalpha/beta, VEGFR1/2/3, KIT, FLT3, CSF-1R, and RET, which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inlyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Sutent
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Inlyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (3/8)
Sutent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Inlyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (2/3)
Sutent
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Sutent Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InlytaView full Inlyta profile
SutentView full Sutent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.